<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83804">
  <stage>Registered</stage>
  <submitdate>14/04/2009</submitdate>
  <approvaldate>19/05/2009</approvaldate>
  <actrnumber>ACTRN12609000304235</actrnumber>
  <trial_identification>
    <studytitle>Bronchoscopic detection of sentinel lymph node in non-small cell lung cancer: a feasibility study</studytitle>
    <scientifictitle>A feasibility study in developing a novel technique for bronchoscopic detection of sentinel lymph node in non-small cell lung cancer patients</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Non-small cell lung cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Bronchoscopic injection, via transbronchial needle introduced into submucosal layer of bronchial wall, of technetium-99 (antimony colloid) into region of lung in which lung cancer resides.</interventions>
    <comparator>None - feasibility study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Identification of sentinel lymph node by non-invasive means using Nuclear Medicine imaging</outcome>
      <timepoint>24 hours after bronchoscopy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: risk of pneumothorax
Mode of assessment of outcome: Routine chest x-ray will be performed after each procedure. clinical observatino for a minimum 4 hours post-procedure will also be routine</outcome>
      <timepoint>4 hours after bronchoscopy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients undergoing flexible bronchoscopy for the diagnosis of suspected peripheral lung cancer</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patient declines
Mediastinal lymphadenopathy on computerized tomography (CT) chest
medically unsuitable for bronchoscopy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Bronchoscopic injection of Technetium-99 into carina of lung lobe in which lung mass is stiuated will be performed following diagnostic sampling.
Single Photon Emission computerized tomography combined with conventional computerized tomography (SPECT/CT) chest will be performed in order to visualize drainage of radio-isotope to regional lymph nodes in order to identify sentinel node.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Daniel Steinfort</primarysponsorname>
    <primarysponsoraddress>c/- Dept Respiratory Medicine
Royal Melbourne Hospital
Grattan St
Parkville
Victoria 3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study looks at the feasibility of using Technitium, injected via a bronchoscope, for the detection of the sentinel lymph node in suspected non-small cell lung cancer 

Who is it for? 
You can join this study if you are: - about to undergo flexible bronchoscopy for the diagnosis of suspected non-small cell lung cancer - 40-85 years of age - prepared to accept the 2% risk of developing a pneumothorax (collapsed lung) with this treatment. 

Trial details 
While having their scheduled bronchoscope, participants will receive injection of technetium dye into the region of the lung which has the lung cancer. The technetium will allow any sentinel lymph nodes to be identified by a non-invasive Nuclear Medicine imaging test called a SPECT/CT scans, 4 hours after the injection. The study will look at the effectiveness and safety of this procedure.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>24/04/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Daniel Steinfort</name>
      <address>c/- Dept Respiratory Medicine
Royal Melbourne Hospital
Grattan St
Parkville
Victoria 3050</address>
      <phone>+61 3 9342 7708</phone>
      <fax />
      <email>daniel.steinfort@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Daniel Steinfort</name>
      <address>c/- Dept Respiratory Medicine
Royal Melbourne Hospital
Grattan St
Parkville
Victoria 3050</address>
      <phone>+61 3 9342 7708</phone>
      <fax />
      <email>daniel.steinfort@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>